Notal Vision

Company Overview

Snapshot

Founded in August 2000, Notal Vision operates with 51–200 employees. The company has raised over $94 million across 6 funding rounds from 6 investors. In March 2024, Notal Vision won the Roche for a Better Future program, highlighting its innovative approach to remote monitoring for retinal diseases.

Business overview

Notal Vision develops a cloud-based platform leveraging AI algorithms for diagnostic decision support in ophthalmology. The company's core technology enables at-home testing and patient-activated treatment for retinal diseases, operating on a monthly recurring subscription model. Its offerings include ForeseeHome, an FDA-approved home monitoring test for early detection of wet age-related macular degeneration (AMD), and home optical coherence tomography (OCT) solutions for noninvasive retinal imaging. Notal Vision serves patients with retinal diseases and healthcare providers, operating within the Digital Medical Diagnostics sector of Health Tech & Life Sciences.

Strategic signal

Notal Vision recently secured a significant win in March 2024 by being selected for the Roche for a Better Future program. This partnership with Roche Israel and Beilinson Hospital validates Notal Vision's AI-driven remote monitoring technology for retinal diseases, signaling strong industry recognition and a pathway for further clinical research and market expansion.

Company Intelligence Q&A

What was a significant recent achievement for Notal Vision?

In March 2024, Notal Vision won the Roche for a Better Future program. This recognition highlights the company's patient-focused digital health services for remote monitoring of retinal diseases and will support clinical research at Beilinson Hospital with Roche Israel.

What was the outcome of Notal Vision's U.S. Home OCT study?

In March 2022, Notal Vision reported the publication of results from the first U.S.-based study of its investigational home-based optical coherence tomography (OCT) platform. The study demonstrated over 95% agreement in retinal fluid detection compared to in-office OCT, indicating significant potential for managing wet age-related macular degeneration (AMD).

Which investors participated in Notal Vision's Series D funding round?

In June 2021, Notal Vision closed a Series D financing round. Investors included Soleus Capital and Elron Ventures.

What was the strategic partnership formed by Notal Vision in early 2021?

In February 2021, Notal Vision partnered with AsclepiX Therapeutics to provide Home OCT monitoring services for their clinical trial program. This collaboration aims to enrich clinical trial datasets and reduce the burden of frequent office visits for patients with retinal diseases.

When did Notal Vision's Home OCT receive FDA Breakthrough Device designation?

In December 2018, Notal Vision's Home OCT system was granted Breakthrough Device designation by the FDA, recognizing its potential to provide automated identification of intra- and/or subretinal fluid in exudative age-related macular degeneration.